Blennow K - Search Results

1

Gut inflammation associated with age and Alzheimer's disease pathology: a human cohort study.

Heston MB, Hanslik KL, Zarbock KR, Harding SJ, Davenport-Sis NJ, Kerby RL, Chin N, Sun Y, Hoeft A, Deming Y, Vogt NM, Betthauser TJ, Johnson SC, Asthana S, Kollmorgen G, Suridjan I, Wild N, Zetterberg H, Blennow K, Rey FE, Bendlin BB, Ulland TK. Heston MB, et al. Among authors: blennow k. Sci Rep. 2023 Nov 14;13(1):18924. doi: 10.1038/s41598-023-45929-z. Sci Rep. 2023. PMID: 37963908 Free PMC article.

2

The neurochemistry of Alzheimer's disease.

Blennow K, Cowburn RF. Blennow K, et al. Acta Neurol Scand Suppl. 1996;168:77-86. doi: 10.1111/j.1600-0404.1996.tb00378.x. Acta Neurol Scand Suppl. 1996. PMID: 8997425 Review.

3

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Blennow K, Vanmechelen E, Hampel H. Blennow K, et al. Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. doi: 10.1385/MN:24:1-3:087. Mol Neurobiol. 2001. PMID: 11831556 Review.

4

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

Sjögren M, Davidsson P, Wallin A, Granérus AK, Grundström E, Askmark H, Vanmechelen E, Blennow K. Sjögren M, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2002;13(2):112-8. doi: 10.1159/000048642. Dement Geriatr Cogn Disord. 2002. PMID: 11844893

5

The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease.

Zetterberg H, Nexö E, Regland B, Minthon L, Boson R, Palmér M, Rymo L, Blennow K. Zetterberg H, et al. Among authors: blennow k. Clin Chem. 2003 Jul;49(7):1195-8. doi: 10.1373/49.7.1195. Clin Chem. 2003. PMID: 12816923 No abstract available.

6

CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.

Blennow K, Vanmechelen E. Blennow K, et al. Brain Res Bull. 2003 Aug 15;61(3):235-42. doi: 10.1016/s0361-9230(03)00086-8. Brain Res Bull. 2003. PMID: 12909293 Review.

7

CSF markers for incipient Alzheimer's disease.

Blennow K, Hampel H. Blennow K, et al. Lancet Neurol. 2003 Oct;2(10):605-13. doi: 10.1016/s1474-4422(03)00530-1. Lancet Neurol. 2003. PMID: 14505582 Review.

8

Cerebrospinal fluid markers for prediction of Alzheimer's disease.

Zetterberg H, Wahlund LO, Blennow K. Zetterberg H, et al. Among authors: blennow k. Neurosci Lett. 2003 Nov 27;352(1):67-9. doi: 10.1016/j.neulet.2003.08.011. Neurosci Lett. 2003. PMID: 14615052

9

Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.

Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreasen N, Lenhard B, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Johansson A, et al. Among authors: blennow k. Hum Genet. 2004 May;114(6):581-7. doi: 10.1007/s00439-004-1107-9. Epub 2004 Mar 18. Hum Genet. 2004. PMID: 15034781

10

APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. Prince JA, et al. Among authors: blennow k. Neurology. 2004 Jun 8;62(11):2116-8. doi: 10.1212/01.wnl.0000128088.08695.05. Neurology. 2004. PMID: 15184629

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,088 results

Search Page